Explore Products
Tumor Cell Lines

Panc 10.05

  • BSL

    1

  • 202
Panc 10.05 Is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma.
Request Your Custom Quote Today

Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.

Get a Quote
  • High Purity Levels
  • Precision and Reliability
  • Customization Options
Product Code

Panc-10.05; Panc10.05; PANC-10-05; PANC 1005; PANC1005; Panc1005; Pa16C; PL12; PL-12

Species

Human

Cat.No

ABC-TC0900

Product Category Tumor Cell Lines
Size/Quantity

1 vial

Cell Type

Epithelial

Shipping Info

Dry Ice

Growth Conditions

37 ℃, 5% CO2

Source Organ

Pancreas

Disease

Adenocarinoma

Biosafety Level

1

Storage

Liquid Nitrogen

Product Type

Human Pancreas Cancer Cell Lines

Description

Panc 10.05Panc 10.05 is a human pancreatic ductal adenocarcinoma (PDAC) cell line established in 1992 from a primary pancreatic adenocarcinoma of an 81-year-old male patient. This cell line exhibits an epithelial-like morphology with adherent growth properties and a doubling time of approximately 20~30 hours (1). Panc 10.05 carries the KRAS G12D mutation – an oncogenic driver frequently observed in PDAC. As well, they express epithelial markers including cytokeratin 7/18. The cell line is tumorigenic in immunocompromised mice, making it suitable for in vivo studies of pancreatic cancer progression.

View Product Image

Citation

When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).

Application

  • Panc 10.05 cell line serves as a valuable tool for pancreatic cancer research, particularly for evaluating therapeutic strategies targeting KRAS-driven oncogenesis. Its genetic profile and tumorigenic behavior make it an effective model for assessing cell proliferation, apoptosis and tumor growth inhibition in response to experimental treatments. Furthermore, Panc 10.05 is suitable for xenograft studies, where its moderate tumorigenicity supports the preclinical evaluation of potential anti-angiogenic agents, cytotoxic compounds and targeted therapies. This cell line contributes to the advancement of precision medicine approaches in pancreatic ductal adenocarcinoma.

Inquiring Panc 10.05

We know how valuable your research is to you, but are you wondering what you can expect to pay for quick accurate results every time? Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
High Viability
To succeed in cell culture
Precision and Reliability
To support a consistent result
Customization Options
Tailed to your research

Tags

AcceGen Scroll Top Button